Search Results

Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpot™ ATP-Max KinomeScreen at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 7-10, 2024, in San Diego, California.

ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.

Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium , May 17th, 2024 at the Mission Bay Conference Center in San Francisco.

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert shares his insights on these in-demand roles.

ARS Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the application for marketing authorization for EURneffy® and recommended related market authorization in the European Union for the emergency treatment of allergic reactions.

Approximately 10% of people diagnosed with cancer experience hypersensitivity reactions to certain therapies—which range from a mild skin rash to anaphylaxis —even when they were pretreated with antihistamines and steroids.

Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL1 in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD).